12 Jul 2026

CRC Research Update — July 12, 2026

Creator: The CRC Digest
Published: 2026-07-12T11:43:14Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

Plasmonic liquid biopsy platform expanded to early-stage colorectal cancer
Researchers have extended a plasmonic liquid biopsy platform to detect early-stage colorectal cancer, potentially improving non-invasive screening options. (Medical Xpress)
PICC-2 trial: Toripalimab plus celecoxib improves pathologic complete response in dMMR locally advanced colorectal cancer
The combination of toripalimab (an immunotherapy) with celecoxib increased pathologic complete response rates in patients with mismatch repair-deficient (dMMR) locally advanced colorectal cancer. (Oncodaily)
Chinese herbal formula prevents oxaliplatin-induced neuropathy in multicenter randomized trial
A multicenter, randomized, double-blind, placebo-controlled trial at 12 tertiary hospitals found that Huangqi Guizhi Wuwu Decoction (HQGZWWD), a traditional Chinese herbal formula, was effective in preventing oxaliplatin-induced peripheral neuropathy, which affects up to 80% of patients receiving oxaliplatin-based chemotherapy. (Phytomedicine)
Systematic review examines Fusobacterium nucleatum as predictor of treatment response
A systematic review evaluated whether Fusobacterium nucleatum, a bacterium implicated in CRC progression and immune modulation, can predict treatment response, though its role as a biomarker remains unclear. (Cancer Treatment Reviews)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Prolonged diagnostic delays linked to advanced-stage presentation in early-onset CRC in Mexico
(Cureus)
Ohio study compares risk factors between early-onset and late-onset colorectal cancer
Researchers examined demographic, lifestyle, and clinical risk factors that differ between patients diagnosed before age 50 versus those diagnosed at 50 or older. (Cancer Causes & Control)

⚥ Sex & Gender in CRC

Research on sex-specific differences in treatment, outcomes, and screening

Y-linked RNA helicase DDX3Y may act as tumor suppressor in male colorectal cancer
First evidence shows DDX3Y, a Y chromosome gene, is downregulated in male CRC tumors and may help explain why men experience higher incidence, metastasis, and mortality rates. (Biochemical Genetics)

Stay informed, and remember that research is a journey—each finding brings us closer to better care.

Subscribe to The CRC Digest